Oncology · Clinical trials
Gastrointestinal Stromal Tumour (GIST) Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About gastrointestinal stromal tumour (gist) — and why its trials are hard
Gastrointestinal stromal tumours are the most common mesenchymal neoplasms of the GI tract, arising from the interstitial cells of Cajal and driven in roughly 80% of cases by activating KIT mutations and in about 5-10% by PDGFRA mutations. GIST is the landmark success story of targeted therapy in solid tumours: before imatinib, metastatic disease was chemotherapy- and radiotherapy-refractory with dismal survival. Sequential tyrosine kinase inhibitors now define care across lines, matched increasingly to specific mutations (exon 11, exon 9, PDGFRA D842V). Surgery remains curative for localised disease, with adjuvant imatinib for high-risk resected tumours. Key challenges include acquired resistance through secondary KIT mutations, the historically drug-resistant PDGFRA D842V subtype (now addressed by avapritinib), and rare wild-type/SDH-deficient and paediatric variants that respond poorly to standard TKIs. Molecular genotyping at diagnosis is now standard to guide first-line selection and sequencing, making GIST a model for precision oncology in a rare tumour.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Imatinib (Gleevec/Glivec) | 2002 | First-line unresectable/metastatic KIT+ GIST; also adjuvant after resection (2008, extended 2012) | B2222 (phase 2); adjuvant ACOSOG Z9001, SSGXVIII/AIO | Objective response rate; recurrence-free survival (adjuvant) | ORR ~68% in B2222; 3 years adjuvant improved RFS and overall survival vs 1 year in SSGXVIII |
| Sunitinib (Sutent) | 2006 | Second-line after imatinib failure/intolerance | Phase 3 (A6181004) | Time to tumour progression | Median TTP 27.3 vs 6.4 weeks vs placebo |
| Regorafenib (Stivarga) | 2013 | Third-line after imatinib and sunitinib | GRID (phase 3) | Progression-free survival | Median PFS 4.8 vs 0.9 months (HR ~0.27) |
| Avapritinib (Ayvakit/Ayvakyt) | 2020 | Unresectable/metastatic PDGFRA exon 18 (incl. D842V) mutant GIST | NAVIGATOR (phase 1) | Objective response rate | ORR ~84-89% in D842V subtype previously refractory to all TKIs |
| Ripretinib (Qinlock) | 2020 | Fourth-line, after >=3 prior TKIs including imatinib | INVICTUS (phase 3) | Progression-free survival | Median PFS 6.3 vs 1.0 months vs placebo (HR ~0.15) |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in gastrointestinal stromal tumour (gist) development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Nilotinib — ENESTg1 (phase 3, first-line vs imatinib) | Did not demonstrate superiority/non-inferiority to imatinib in first-line GIST | Imatinib set a very high efficacy bar; nilotinib CNS/GI penetration and mutation coverage insufficient to displace it |
| Ripretinib — INTRIGUE (phase 3, second-line vs sunitinib) | Failed to beat sunitinib on PFS in overall second-line population | Benefit confined to KIT exon 11 mutant subset; broad all-comer design diluted signal |
Choosing the right endpoint
Primary endpoints that matter in gastrointestinal stromal tumour (gist) trials
- Progression-free survival (PFS) — Primary endpoint in most later-line TKI trials (GRID, INVICTUS); robust in a disease where responses are often stabilisation rather than shrinkage
- Objective response rate (ORR) — Key for accelerated/mutation-specific approvals (B2222, NAVIGATOR); Choi criteria (density plus size) often more sensitive than RECIST for TKI effect
- Recurrence-free survival (RFS) — Primary adjuvant endpoint (Z9001, SSGXVIII) capturing delay of relapse after complete resection
- Overall survival (OS) — Gold standard but confounded by crossover and effective post-progression TKI sequencing
- Time to progression (TTP) — Used in the pivotal sunitinib trial; excludes non-progression deaths
How iNGENū runs gastrointestinal stromal tumour (gist) trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Gastrointestinal Stromal Tumour (GIST) clinical trials — FAQs
Why is GIST considered a model for targeted therapy?
Why does GIST eventually stop responding to imatinib?
What made PDGFRA D842V historically untreatable?
Ready to discuss your gastrointestinal stromal tumour (gist) trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal